Redian新闻
>
Is it true or not about BCRX?
avatar
Is it true or not about BCRX?# Stock
b*7
1
http://seekingalpha.com/article/182425-biocryst-peramivir-approval-opens-japanese-market
BioCryst Pharmaceuticals (BCRX) announced that their Jpanaese partner,
Shionogi & Co., has been granted approval for peramivir in Japan, triggering
the third $7 million clinical development milestone payment from Shionogi
to BioCryst. BioCryst will receive an additional $95 million as commercial
milestones are achieved. In addition, BioCryst receives a 10% to 20% royalty
on Shionogi's sales, and will capture
avatar
b*7
2
Based on his caculation, the Japan market itself will push the stock price
to 20-30$. Why the price still is only $ 8?

triggering
royalty
in
peramivir

【在 b******7 的大作中提到】
: http://seekingalpha.com/article/182425-biocryst-peramivir-approval-opens-japanese-market
: BioCryst Pharmaceuticals (BCRX) announced that their Jpanaese partner,
: Shionogi & Co., has been granted approval for peramivir in Japan, triggering
: the third $7 million clinical development milestone payment from Shionogi
: to BioCryst. BioCryst will receive an additional $95 million as commercial
: milestones are achieved. In addition, BioCryst receives a 10% to 20% royalty
: on Shionogi's sales, and will capture

相关阅读
logo
联系我们隐私协议©2024 redian.news
Redian新闻
Redian.news刊载任何文章,不代表同意其说法或描述,仅为提供更多信息,也不构成任何建议。文章信息的合法性及真实性由其作者负责,与Redian.news及其运营公司无关。欢迎投稿,如发现稿件侵权,或作者不愿在本网发表文章,请版权拥有者通知本网处理。